Berman Tabacco represents the proposed class in this class action brought under federal and state antitrust laws and state consumer-protection and unjust-enrichment laws alleging that defendant Novo Nordisk embarked on an anticompetitive scheme to delay generic competition for Victoza, its blockbuster GLP-1 diabetes drug. The action seeks to recover the overcharges sustained by end-payors for brand-name Victoza and its generic equivalents, and to enjoin further monopolistic conduct by Novo Nordisk.
